Possible contribution of C-reactive protein within coronary plaque to increasing its own plasma levels across coronary circulation

Ishikawa, Tetsunori; Imamura, Takuroh; Hatakeyama, Kinta; Date, Hiroyuki; Nagoshi, Toshiro; Kawamoto, Riichirou; Matsuyama, Akihiko; Asada, Yujiro; Eto, Tanenao

doi:10.1016/j.amjcard.2003.11.030

Cited by 42 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to the cardiovascular system, several studies have shown a strong correlation between high blood CRP level and CVD [7,8]. In acute coronary syndrome, high CRP levels have been found in the coronary sinus, suggesting the presence of CRP in cardiac tissue [9]. Postmenopausal women have an elevated risk for coronary heart disease and atherosclerotic events resulting from reduced estrogen levels and loss of the cardioprotective action of estrogen [10,11].…”

Section: Introductionmentioning

confidence: 99%

Tamoxifen Alters the Plasma Concentration of Molecules Associated with Cardiovascular Risk in Women with Breast Cancer Undergoing Chemotherapy

et al. 2012

View full text Add to dashboard Cite

Objectives. The objective of this study was to evaluate the effect of tamoxifen on blood markers that are associated with cardiovascular risk, such as C-reactive protein (CRP), apolipoprotein A-1 (Apo-A), and apolipoprotein B-100 (Apo-B), in women undergoing chemotherapy for breast cancer.Methods. Over a period of 12 months, we followed 60 women with breast cancer. The women were divided into the following groups: a group that received only chemotherapy (n ‫؍‬ 23), a group that received chemotherapy plus tamoxifen (n ‫؍‬ 21), and a group that received only tamoxifen (n ‫؍‬ 16). Plasma CRP levels were assessed at 0, 3, 6, and 12 months, and Apo-A and Apo B levels as well as the Apo-B/Apo-A ratio were assessed at 0 and 12 months.Results. We found increases in the plasma concentration of CRP in the chemotherapy alone and chemotherapy plus tamoxifen groups after 3 and 6 months of treatment (before the introduction of tamoxifen). However, after 12 months of treatment, women who used tamoxifen (the chemotherapy plus tamoxifen and tamoxifen alone groups) showed a significant reduction in CRP and Apo-B levels and a decrease in the Apo-B/Apo-A ratio. A significant increase in serum Apo-A levels was observed in the group receiving chemotherapy alone as a treatment for breast cancer.Conclusion. The use of tamoxifen after chemotherapy for the treatment of breast cancer significantly reduces the levels of cardiovascular disease risk markers (CRP, Apo-B, and the Apo-B/Apo-A ratio). The Oncologist 2012;17: 499 -507

show abstract

Section: Introductionmentioning

confidence: 99%

Tamoxifen Alters the Plasma Concentration of Molecules Associated with Cardiovascular Risk in Women with Breast Cancer Undergoing Chemotherapy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…It is synthesized and secreted primarily in hepatocytes (54) and regulated by interleukin-6 (IL-6), interleukin-1 (IL-1), and tumor necrosis factor-alpha (TNF á ) (78). It has, however, been reported that in patients with acute coronary syndrome CRP is localized in the vessel wall and its levels are higher in the coronary sinus than in the aorta, suggesting a cardiac source of CRP (56,57). The normal plasma level of CRP in a healthy population without evidence of acute inflammation is 2 mg/L or less (48).…”

Section: Introductionmentioning

confidence: 99%

C‐Reactive Protein (CRP)‐Lowering Agents

Prasad

2006

Cardiovascular Drug Reviews

237

185

View full text Add to dashboard Cite

C-reactive protein (CRP) plays a role in the pathogenesis of cardiovascular disease. It is a marker and predictor of cardiovascular disease. CRP possesses numerous cardiovascular effects (clotting, generation of oxygen radicals, increase in the expression of adhesion molecules and plasminogen activator inhibitor-1, plaque destabilization) that could result in cardiovascular disease. This review describes the effects of various cardiovascular drugs on the levels of CRP in health and disease. Cyclooxygenase inhibitors (aspirin, rofecoxib, celecoxib), platelet aggregation inhibitors (clopidogrel, abciximab), lipid lowering agents (statins, ezetimibe, fenofibrate, niacin, diets), â-adrenoreceptor antagonists and antioxidants (vitamin E), as well as angiotensin converting enzyme (ACE) inhibitors (ramipril, captopril, fosinopril), reduce serum levels of CRP; while enalapril and trandolapril have not been shown to have the same effect. Angiotensin receptor blockers (ARBs) (valsartan, irbesartan, olmesartan, telmisartan) markedly reduce serum levels of CRP. The findings with other ARBs (losartan and candesartan) were inconsistent. Antidiabetic agents (rosiglitazone and pioglitazone) reduce CRP levels, while insulin is ineffective. Calcium channel antagonists have variable effects on CRP levels. Hydrochlorothiazide and oral estrogen do not affect CRP. The CRP-lowering effect of statins is more pronounced than their lipid lowering effect and is not dependent on their hypolipemic activity. The effect of atorvastatin on CRP seems to be dose-dependent. CRP-lowering effect of statins is likely to contribute to the favorable outcome of statin therapy. The data suggest that lipid lowering agents, ACE inhibitors, ARBs, antidiabetic agents, antiinflammatory and antiplatelet agents, vitamin E, and â-adrenoreceptor antagonists lower serum or plasma levels of CRP, while vitamin C, oral estrogen and hydrochlorothiazide do not affect CRP levels.

show abstract

“…In a recent report, Ishikawa et al . demonstrated that the gene for CRP was expressed in coronary plaque tissue obtained during the atherectomy procedure [17].…”

Section: Introductionmentioning

confidence: 99%

Leptin, soluble interleukin-6 receptor, C-reactive protein and soluble vascular cell adhesion molecule-1 levels in human coronary atherosclerotic plaque

Karaduman¹,

Öktenli²,

Muşabak³

et al. 2006

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryThe aim of the present study was to explore the relationship between tissue levels of leptin, soluble interleukin-6 receptor (sIL-6R), high-sensitive-C-reactive protein (hs-CRP) and soluble vascular cell adhesion molecule-1 (sVCAM-1) in atherosclerotic plaques, and traditional risk factors. Coronary artery specimens were obtained from 35 consecutive patients (26 men and nine women) who underwent coronary artery bypass grafting procedure. The mean tissue levels of leptin, hs-CRP and sIL-6R were significantly higher in patients with diabetes mellitus than without diabetes mellitus. When patients were classified according to the smoking status, the mean tissue levels of leptin, hs-CRP and sIL-6R were significantly higher in current smokers than both former smokers and non-smokers. In addition, the mean tissue levels of leptin and sIL-6R were significantly higher in former smokers than non-smokers. There was a positive association between leptin and hs-CRP, sIL-6R and plasma glucose in all patients. Plasma HDL levels were associated negatively with atherosclerotic tissue levels of leptin. Tissue levels of sIL-6R were associated significantly in a positive manner with leptin, hs-CRP and plasma glucose, while tissue levels of hs-CRP were associated with both leptin and sIL-6R. In conclusion, it is attractive to speculate that hs-CRP, sIL-6R and leptin could act synergistically in course of local inflammatory activity and those molecules may not be just markers of inflammation and cardiovascular risk but are also likely to play a pathogenic role in atheromatous plaque. In addition, atherosclerotic tissue levels of CRP, sIL-6R and leptin were significantly higher in current smokers and patients with diabetes.

show abstract

Possible contribution of C-reactive protein within coronary plaque to increasing its own plasma levels across coronary circulation

Cited by 42 publications

References 17 publications

Tamoxifen Alters the Plasma Concentration of Molecules Associated with Cardiovascular Risk in Women with Breast Cancer Undergoing Chemotherapy

Tamoxifen Alters the Plasma Concentration of Molecules Associated with Cardiovascular Risk in Women with Breast Cancer Undergoing Chemotherapy

C‐Reactive Protein (CRP)‐Lowering Agents

Leptin, soluble interleukin-6 receptor, C-reactive protein and soluble vascular cell adhesion molecule-1 levels in human coronary atherosclerotic plaque

Contact Info

Product

Resources

About